The EVITA trial evaluated oral vitamin C (1000 mg/day for 12 months) vs. placebo in 109 adults with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies (MDS, CMML 0/1) not on anticancer therapy, with primary endpoint of clonal growth rate and follow-up through September 2023.
The primary endpoint—median clonal growth rate—did not differ between groups (between-group difference −0.016; 95% CI, −0.096 to 0.064; p = .70). However, fewer serious adverse events occurred in the vitamin C arm (33% vs. 57%), inflammatory cytokines (IL-6, IL-10, CXCL10, M-CSF, G-CSF) rose less in the vitamin C group, and in exploratory analyses overall survival was significantly longer with vitamin C (HR 0.35; 95% CI, 0.17–0.71; p = .0025; median OS not reached vs. 42.2 months with placebo).
No formal sample size calculation was performed, leaving the trial underpowered to detect modest effects on the primary endpoint. Treatment was limited to 12 months with no post-treatment vitamin C controls, risking informal crossover that may have influenced long-term survival. Baseline imbalances (higher mutational burden and worse prognostic scores in the vitamin C group) could confound exploratory survival results despite multivariable adjustment.
Oral vitamin C 1000 mg/day appears safe and biologically active in patients with CCUS or lower-risk myeloid malignancies, but it did not reduce clonal growth over 12 months—the survival signal is hypothesis-generating only and should not change current management. A phase 3 trial is needed before routine use can be recommended.